Pathway Genomics has launched its BreastTrue High Risk Panel, a next-generation sequencing-based assay with deletion/duplication analysis to detect mutations in seven high-risk cancer susceptibility genes — BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, and TP53. The test can analyze DNA from either blood or saliva. In addition, it has now added the option for customers that test negative using its BRCATrue and BRCATrue Ashkenazi Jewish panels to reflex to the BreastTrue panel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.